Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis
ConclusionBased on this analysis, rivaroxaban seemed to be a better option in comparison to warfarin, due to its association with significantly lower risks of stroke and bleeding outcomes in obese patients with non-valvular AF. However, this hypothesis should further be confirmed in larger clinical trials.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Cardiovascular | Clinical Trials | Coumadin | Databases & Libraries | Eating Disorders & Weight Management | Heart | Hemorrhagic Stroke | Ischemic Stroke | Obesity | Science | Stroke | Study | Warfarin